Bill Text: TX HB2462 | 2023-2024 | 88th Legislature | Introduced
Bill Title: Relating to disclosure of certain complaint and investigation information by the Texas State Board of Pharmacy to the United States Food and Drug Administration.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2023-04-24 - Left pending in committee [HB2462 Detail]
Download: Texas-2023-HB2462-Introduced.html
88R2171 KBB-F | ||
By: Klick | H.B. No. 2462 |
|
||
|
||
relating to disclosure of certain complaint and investigation | ||
information by the Texas State Board of Pharmacy to the United | ||
States Food and Drug Administration. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Section 555.010, Occupations Code, is amended to | ||
read as follows: | ||
Sec. 555.010. CONFIDENTIALITY; AUTHORIZED DISCLOSURE. (a) | ||
Subject to Subsection (b), the [ |
||
reports to or assists the board under Section 555.002(c) and a | ||
document that could disclose the identity of that person are | ||
confidential and are not considered public information for the | ||
purposes of Chapter 552, Government Code. | ||
(b) The identity of a person described by Subsection (a) and | ||
a document that could disclose the identity of that person may be | ||
disclosed to the United States Food and Drug Administration under a | ||
memorandum of understanding described by Section 503A, Federal | ||
Food, Drug, and Cosmetic Act (21 U.S.C. Section 353a(b)(3)(B)), | ||
entered into as provided by that section. | ||
SECTION 2. Section 565.055(c), Occupations Code, is amended | ||
to read as follows: | ||
(c) Notwithstanding Subsection (b), information or material | ||
compiled by the board in connection with an investigation may be | ||
disclosed: | ||
(1) during any proceeding conducted by the State | ||
Office of Administrative Hearings, to the board, or a panel of the | ||
board, or in a subsequent trial or appeal of a board action or | ||
order; | ||
(2) to a person providing a service to the board, | ||
including an expert witness, investigator, or employee of an entity | ||
that contracts with the board, related to a disciplinary proceeding | ||
against an applicant or license holder, or a subsequent trial or | ||
appeal, if the information is necessary for preparation for, or a | ||
presentation in, the proceeding; | ||
(3) to an entity in another jurisdiction that: | ||
(A) licenses or disciplines pharmacists or | ||
pharmacies; or | ||
(B) registers or disciplines pharmacy | ||
technicians or pharmacy technician trainees; | ||
(4) to a pharmaceutical or pharmacy peer review | ||
committee as described under Chapter 564; | ||
(5) to a law enforcement agency; | ||
(6) to a person engaged in bona fide research, if all | ||
information identifying a specific individual has been deleted; | ||
[ |
||
(7) to an entity that administers a board-approved | ||
pharmacy technician certification examination; or | ||
(8) to the United States Food and Drug Administration | ||
under a memorandum of understanding described by Section 503A, | ||
Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section | ||
353a(b)(3)(B)), entered into as provided by that section. | ||
SECTION 3. This Act takes effect September 1, 2023. |